The Philips V60 Discontinuation:
A $1 Billion Window That Will Not Stay Open
When Philips discontinued the V60 ventilator — the dominant non-invasive ventilation (NIV) platform in ICUs across North America, Europe, and Asia-Pacific — it created a significant opportunity for manufacturers seeking to expand their critical care portfolio. This is more than a product replacement cycle; it is a rare opportunity to enter an established global market with a proven clinical need.
The Philips V60 held an estimated 40% share of the global non-invasive ventilation market at its peak. Following its discontinuation, hospitals worldwide have been evaluating alternative NIV platforms that provide equivalent clinical performance while meeting today's expectations for connectivity, portability, and future-ready software capabilities.
The box ventilator from IMT Innovations is engineered to exceed the clinical specifications of the Philips V60. Featuring an advanced pneumatic platform, dual-limb capability, adult and pediatric ventilation modes, and an AI-ready architecture, box is designed to address the full spectrum of patients previously served by the V60 while delivering enhanced synchrony, portability, and connectivity.
Our licensing model enables manufacturers to enter this market without investing a decade in product development. Validation activities have started, with CE certification and FDA 510(k) submission planned for 2027. The complete technical package is being prepared for transfer, providing licensing partners with a clear pathway to accelerate market entry.
As hospitals continue replacing legacy V60 systems over the coming years, manufacturers that establish their position early will be well placed to secure institutional relationships, build clinical reference sites, and capture long-term market share. Early engagement provides the greatest opportunity to participate in this transition.
The IMT Innovations Licensing Information Memorandum — including market analysis, commercial opportunity, licensing structure, and development roadmap — is available to qualified manufacturers and strategic partners upon request.
We welcome confidential discussions with organizations interested in licensing the box ventilator platform.
